

## Pharmaceuticals Company Overview of Mylan Pharmaceuticals Inc.

November 16, 2015 6:24 PM ET

Snapshot

People

### Company Overview

Mylan Pharmaceuticals Inc. researches, develops, manufactures, markets, and distributes generic pharmaceutical products. Its products include amlodipine besylate and atorvastatin calcium tablets for the treatment of hypertension; levetiracetam extended-release tablets for the treatment of partial onset seizures in patients of over 16 years of age with epilepsy; eprosartan mesylate tablets for treating hypertension; doxycycline hyclate delayed-release tablets; and fluvastatin capsules for the treatment of familial and nonfamilial hypercholesterolemia, mixed dyslipidemia, and secondary prevention of cardiovascular diseases. The company also provides olanzapine tablets for the treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar 1 disorder, and maintenance treatment of bipolar 1 disorder; USP tablets for the treatment of hyperprolactinemic disorders; tablets for allergy medication; nevirapine tablets for combination antiretroviral treatment of HIV-1 infection; acyclovir ointment USP for the management of initial genital herpes; and phenytoin chewable tablets for the control of generalized tonic-clonic and partial seizures, and prevention and treatment of seizures occurring during or following neurosurgery. In addition, it offers clopidogrel tablets for acute coronary syndrome; and for patients with a recent history of myocardial infarction, stroke, or established peripheral arterial disease. Further, the company provides norethindrone tablets to prevent pregnancy. Its products are also used for the treatment of angina to arthritis, depression, diabetes, Parkinson's disease, schizophrenia, and sleep disorders. The company was formerly known as Milan Pharmaceuticals Inc. and changed its name to Mylan Pharmaceuticals Inc. in August 1973. The company was founded in 1961 and is based in Morgantown, West Virginia. Mylan Pharmaceuticals Inc. operates as a subsidiary of Mylan N.V.

[Hide Detailed Description](#)

781 Chestnut Ridge Road  
Morgantown, WV 26505  
United States

Phone 724-514-1800

Fax 304-598-5406

Founded in 1961

### Key Executives For Mylan Pharmaceuticals Inc.

**Mr. Joseph Duda**  
President

**Mr. John Deiriggi**  
Senior Vice President

**Ms. Colleen Ostrowski**  
Treasurer  
Age: 41

**Mr. Daniel Caron**  
Vice President of Generic Business Development

Compensation as of Fiscal Year 2015.

### Mylan Pharmaceuticals Inc. Key Developments

#### Appeals Court Affirms Shire plc's Vyvanse (Lisdexamfetamine Dimesylate) Patents Valid Until 2023

Sep 25 15

Shire plc announced that the Court of Appeals of the Federal Circuit has upheld the summary judgment ruling of the U.S. District Court for the District of New Jersey that certain claims of the patents protecting Vyvanse (lisdexamfetamine dimesylate) are valid. Shire's lawsuit included all of the known pharmaceutical manufacturers that filed Abbreviated New Drug Applications with the U.S. Food and Drug Administration seeking to market generic versions of Vyvanse, along with their Active Pharmaceutical Ingredient manufacturer of lisdexamfetamine dimesylate API. The ANDA-defendants are Actavis LLC/Actavis Elizabeth LLC; Amneal Pharmaceuticals, LLC; Mylan Pharmaceuticals Inc./Mylan Inc.; Roxane Laboratories

Inc.; and Sandoz Inc. The API manufacturer and supplier to each of the ANDA-defendants is Johnson Matthey Inc./Johnson Matthey Pharmaceutical Materials. The ruling prevents the ANDA defendants from launching generic versions of Vyvanse until the expiration of these patents in 2023. The defendants may move for rehearing at the Federal Circuit, or may file a petition at the U.S. Supreme Court. The Court of Appeals of the Federal Circuit affirmed the District Court's summary judgment ruling that 18 patent claims from four of the FDA Orange Book-listed patents for Vyvanse are valid. The ANDA defendants' infringement of these claims was not contested on appeal. These patent claims cover Vyvanse's active ingredient, the lisdexamfetamine dimesylate compound, and a method of using lisdexamfetamine dimesylate for the treatment of ADHD. As to the API-manufacturer, the court of appeals of the Federal Circuit found that Johnson Matthey was not liable for the API it sold the ANDA defendants up to this point because it did not submit an ANDA.

### **Noven Pharmaceuticals Inc. and Hisamitsu Pharmaceutical Co., Inc Sues Mylan N.V., Mylan Pharmaceuticals Inc. and Mylan Technologies Inc**

May 5 15

Mylan N.V. confirmed that it and its subsidiaries Mylan Pharmaceuticals Inc. and Mylan Technologies Inc. have been sued by Noven Pharmaceuticals Inc. and Hisamitsu Pharmaceutical Co., Inc., in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Estradiol Transdermal System, USP, "Twice-Weekly" 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day. This product is the generic version of Minivelle®, which is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and the prevention of postmenopausal osteoporosis. Mylan believes that it is the first company, or among the first companies, to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity upon receiving final FDA approval. The plaintiffs filed suit against the Mylan companies in the United States District Court in the District of Delaware.

### **Mylan Pharmaceuticals Inc. Wins \$6,625,235.45 Federal Contract**

May 1 15

Mylan Pharmaceuticals Inc. won a \$6,625,235.45 federal contract from the U.S. Department of Veterans Affairs' National Acquisition Center for loperamide hydrochloride capsule.

#### Similar Private Companies By Industry


Company Name	Region
InCode BioPharmaceutics, Inc.	United States
Supplements Liquidating Trust, LLC	United States
BrainCells Inc.	United States
Antyra, Inc.	United States
Biochemie US, Inc.	United States

#### Recent Private Companies Transactions

Type Date	Target
No transactions available in the past 12 months.	

[Report Data Issue](#)

#### From Around the Web

Sponsored Links by Taboola 

#### **Here's 4 Examples of How Businesses are Using CRM. Sign Up for a Free Demo**

SalesForce

#### **4 in 5 Americans Are Ignoring Buffett's Warning**

The Motley Fool

#### **Meet The Man Who Is Disrupting a \$13 Billion Razor Industry**

Dollar Shave Club

#### **Will This Startup Kill The ETF Revolution?**

Yahoo Finance Motif Investing

#### **Thinking about getting Solar Panels? Read This First**

Solar America

11/16/2015

Mylan Pharmaceuticals Inc.: Private Company Information - Businessweek

**New Law: Turn \$5,000 into \$6.5 Million**

Crowdability